A randomized controlled double-blind study on the brain protection of infantile patients with epileptic spasm syndrome through atomized inhalation of hydrogen-oxygen gas.
Chen Chen, Wen He, Jian Chen, Xiu-Yu Shi, Guang Yang, Jing Wang, Yang-Yang Wang, Pei-Li Hu, Fang Han, Yan Meng, Li-Ping Zou · Frontiers in neurology · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In Both groups received standard treatment plus 4 daily 1-h interventions for 14 consecutive days, although it is generally safe and feasible, its potential effects on myocardial, liver and gastrointestinal functions of children need to be closely monitored. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in Both groups received standard treatment plus 4 daily 1-h interventions for 14 consecutive days. Although it is generally safe and feasible, its potential effects on myocardial, liver and gastrointestinal functions of children need to be closely monitored.
What the Researchers Studied
The researchers studied Both groups received standard treatment plus 4 daily 1-h interventions for 14 consecutive days. The study used a randomized, double-blind human clinical trial.
What Effects Did Molecular Hydrogen Have?
66.6% inhaled H₂ concentration. Although it is generally safe and feasible, its potential effects on myocardial, liver and gastrointestinal functions of children need to be closely monitored.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was Both groups received standard treatment plus 4 daily 1-h interventions for 14 consecutive days. The study used a randomized, double-blind human clinical trial. The reported hydrogen concentration was 66.6% inhaled H₂ concentration.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.